Published in Cell Death Differ on January 01, 2003
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med (2010) 5.76
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene (2011) 1.86
BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res (2008) 1.80
Chemotherapeutic approaches for targeting cell death pathways. Oncologist (2006) 1.70
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A (2005) 1.64
In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas. Neuro Oncol (2008) 1.62
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer (2005) 1.58
TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest (2006) 1.55
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res (2011) 1.54
A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. Mol Cancer Ther (2010) 1.53
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 1.45
Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J (2009) 1.41
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat (2008) 1.39
Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol (2008) 1.39
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol (2009) 1.33
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Radiation, inflammation, and immune responses in cancer. Front Oncol (2012) 1.25
Retracted Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem (2010) 1.24
Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem (2008) 1.23
Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer (2009) 1.23
Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A (2011) 1.22
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell (2004) 1.22
Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells. Mol Biol Cell (2005) 1.21
Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A (2006) 1.18
Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir Res (2005) 1.17
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem (2009) 1.15
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 1.13
Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer (2010) 1.12
CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest (2003) 1.10
Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets (2008) 1.10
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J (2007) 1.08
Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol (2005) 1.07
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis (2010) 1.06
Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol Cell Biol (2007) 1.05
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res (2008) 1.04
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol (2005) 1.04
Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol (2008) 1.04
Intertwined pathways of programmed cell death in immunity. Immunol Rev (2010) 1.04
Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro Oncol (2011) 1.02
Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther (2008) 1.02
Theiler's virus-induced intrinsic apoptosis in M1-D macrophages is Bax mediated and restricts virus infectivity: a mechanism for persistence of a cytolytic virus. J Virol (2008) 1.01
Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med (2009) 1.00
TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene (2009) 0.99
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol (2007) 0.99
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 0.97
Cell biology in neuroscience: Death of developing neurons: new insights and implications for connectivity. J Cell Biol (2013) 0.97
Ganoderma lucidum polysaccharides in human monocytic leukemia cells: from gene expression to network construction. BMC Genomics (2007) 0.96
The EMILIN/Multimerin family. Front Immunol (2012) 0.96
The "fuzzy logic" of the death-inducing signaling complex in lymphocytes. J Clin Immunol (2003) 0.96
Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res (2013) 0.95
ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res (2010) 0.95
Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol (2004) 0.95
TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ (2010) 0.94
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal (2010) 0.94
TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol (2006) 0.94
Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget (2014) 0.93
HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS One (2011) 0.93
Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis (2013) 0.92
KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol (2011) 0.91
Transcriptional targeting of tumor endothelial cells for gene therapy. Adv Drug Deliv Rev (2009) 0.91
Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci (2012) 0.91
RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. Cancer Lett (2007) 0.91
Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis. Clin Exp Immunol (2007) 0.90
Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer (2010) 0.90
Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Exp Cell Res (2010) 0.90
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res (2013) 0.89
Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med (2011) 0.89
Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. Br J Pharmacol (2011) 0.89
Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells. Cell Death Differ (2012) 0.89
PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript. Nat Commun (2014) 0.89
Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. Mol Cancer (2011) 0.88
Dual role of immune cells in the testis: Protective or pathogenic for germ cells? Spermatogenesis (2013) 0.88
The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment. Neoplasia (2010) 0.88
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene (2015) 0.88
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget (2012) 0.88
Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther (2012) 0.87
FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major. Am J Pathol (2007) 0.86
Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ Health Prev Med (2008) 0.86
Potent and tumor specific: arming bacteria with therapeutic proteins. Ther Deliv (2015) 0.86
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine (2011) 0.86
Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res (2006) 0.85
Stellera chamaejasme L. extract induces apoptosis of human lung cancer cells via activation of the death receptor-dependent pathway. Exp Ther Med (2012) 0.85
Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector. Gene Ther (2011) 0.85
Regulating apoptosis in mammalian cell cultures. Cytotechnology (2006) 0.85
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics (2012) 0.85
Mesenchymal stem cells as vectors for lung cancer therapy. Respiration (2013) 0.85
FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res (2013) 0.85
Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int (2012) 0.84
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs (2005) 0.84
Tumor necrosis factor-related apoptosis-inducing ligand alters mitochondrial membrane lipids. Cancer Res (2005) 0.84
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol (1999) 1.63
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 1.46
The syndrome of neonatal copper deficiency. Pediatrics (1973) 1.45
Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death Differ (2006) 1.43
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry (2000) 1.34
Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol (1998) 1.34
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol (1996) 1.33
APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett (1998) 1.32
Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Mol Cell Biol (1996) 1.32
A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature (1992) 1.26
Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. J Biol Chem (1993) 1.20
Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology (1997) 1.14
Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res (2001) 1.10
Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ (2006) 1.09
Histocompatibility determinants in Israeli Jewish patients with coeliac disease: population and family study. Tissue Antigens (1981) 1.08
Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol (2000) 1.07
Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem (1992) 1.06
Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia (2006) 1.04
Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. Biochemistry (1990) 1.02
Coeliac activity of the gliadin peptides CT-1 and CT-2. Z Lebensm Unters Forsch (1986) 1.00
Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci U S A (1995) 0.99
Immunological assay for the diagnosis of coeliac disease: interaction between purified gluten fractions. Pediatr Res (1980) 0.96
Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol (1999) 0.95
Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine (1999) 0.95
A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 0.95
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol (1996) 0.94
Niemann-Pick disease and giant cell transformation of the liver. Acta Paediatr Scand (1971) 0.94
Immunoadhesins: principles and applications. Trends Biotechnol (1996) 0.93
Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry (1993) 0.93
Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J Biol Chem (1992) 0.93
Celiac disease among Ashkenazi Jews from Israel. A study of the HLA class II alleles and their associations with disease susceptibility. Hum Immunol (1993) 0.93
Nocturnal acute laryngospasm in children: a possible epileptic phenomenon. J Child Neurol (2000) 0.92
An in-vitro immunological assay for diagnosis of coeliac disease. Lancet (1978) 0.92
Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest (1995) 0.91
Amino-acid sequence of the coeliac active gliadin peptide B 3142. Z Lebensm Unters Forsch (1984) 0.90
Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur J Pediatr (1986) 0.89
Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Ther (2006) 0.87
Structural basis of muscarinic acetylcholine receptor subtype diversity. Trends Pharmacol Sci (1988) 0.87
Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth. Trends Pharmacol Sci (1989) 0.86
Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Res (2000) 0.85
Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol (1994) 0.85
Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2. J Immunol (1999) 0.85
Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood (1994) 0.85
Electrosleep therapy in bronchial asthma. Int Arch Allergy Appl Immunol (1969) 0.84
Toxicity of different wheat gliadins in coeliac disease. Z Lebensm Unters Forsch (1982) 0.83
In vitro cell-mediated immunologic assay for cow's milk allergy. Pediatrics (1980) 0.83
Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J Infect Dis (1994) 0.82
Control of apoptosis signaling by Apo2 ligand. Recent Prog Horm Res (1999) 0.82
Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin. Immunology (1993) 0.81
CD4 immunoadhesins in anti-HIV therapy: new developments. Int J Cancer Suppl (1992) 0.81
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J Immunol (1994) 0.81
Coeliac disease in the Rehovot-Ashdod region of Israel: incidence and ethnic distribution. J Epidemiol Community Health (1984) 0.81
The value of urinary beta-glucuronidase activity in the assessment of urinary tract infections. Isr J Med Sci (1969) 0.81
The third intracellular loop of the 5-hydroxytryptamine2A receptor determines effector coupling specificity. J Neurochem (1995) 0.80
Molecular and biological properties of an interleukin-1 receptor immunoadhesin. Mol Immunol (1994) 0.80
Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. Mol Immunol (1994) 0.80
Mumps-associated acute cerebellar ataxia. Am J Dis Child (1992) 0.80
Familial infantile renal tubular acidosis and congenital nerve deafness: an autosomal recessive syndrome. Clin Genet (1973) 0.80
Gluten and autism. Lancet (1980) 0.79
Binding sites of human growth hormone and ovine and bovine prolactins in the mammary gland and the liver of lactating dairy cow. Mol Cell Endocrinol (1984) 0.79
Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am J Kidney Dis (1998) 0.79
A muscle disorder as presenting symptom in a child with mucolipidosis IV. Neuropediatrics (1983) 0.79
Highly sensitive amperometric immunosensor for the detection of Escherichia coli. Biosens Bioelectron (2009) 0.79
Periodic autonomic dysfunction without pain in a patient with cluster headache. Cephalalgia (2004) 0.79
Characterization of lactogen receptors in lactogenic hormone-dependent and independent NB2 lymphoma cell lines. FEBS Lett (1987) 0.78
Occipital nerve block rapidly eliminates allodynia far from the site of headache: a case report. Cephalalgia (2004) 0.78
Isolation of coeliac active peptide fractions from gliadin. Z Lebensm Unters Forsch (1983) 0.78
Immunologic reaction of psychotic patients to fractions of gluten. Am J Psychiatry (1979) 0.78
Immune deficiency of T system with possible T cell regulatory activity defect. Isr J Med Sci (1977) 0.78
Partial purification and characterization of bovine mammary gland prolactin receptor. Mol Cell Endocrinol (1987) 0.78
Serum ferritin levels in celiac disease. Am J Clin Pathol (1982) 0.77
Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim Biophys Acta (1994) 0.77
Benign abducens nerve palsy of childhood. Pediatr Neurol (1994) 0.77
Fatal pericardial tamponade complicating total parenteral nutrition via a silastic central vein catheter. J Pediatr Gastroenterol Nutr (1988) 0.76